/ /

  • linkedin
  • Increase Font
  • Sharebar

    Bausch + Lomb unveils enVista IOL reusable injector


    Bridgewater, NJ—Bausch + Lomb have announced the U.S. introduction of BLIS (Bausch + Lomb Injector System), designed exclusively for use with the enVista glistening-free, hydrophobic acrylic IOL.

    The injector—complete with a reusable hand piece and single-use cartridge—allows surgeons safe, controlled delivery of the IOL through unenlarged phaco incisions as small as 2.2 mm.

    “With the addition of (the injector), Bausch + Lomb is proud to provide surgeons with a full system intended specifically for enVista implantation,” said Cal Roberts, MD, chief medical officer, Bausch + Lomb. “This new injector will help surgeons and their staff provide exceptional IOL technology to their cataract patients, helping them see better to live better.

    The injector was developed with the input from surgeons around the world with the ultimate goal of securely and accurately implanting the IOL while minimizing mishandling, loading errors, and damage to the lens.

    The reusable hand piece is made of high-quality titanium material designed for both reliability and comfort for the surgeon and staff. In addition, the proprietary disposable cartridge is designed for easy lens loading, easy wound entry, and smooth delivery of the IOL.

    The injector received Health Canada approval this past August, and CE Mark approval in October. Additional approvals are pending worldwide.


    For more articles in this issue of Ophthalmology Times eReport, click here.



    To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.


    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results